May 11, 2026
Post-TTLC 2026: Dr. Patel asks how supportive care demands, quality of life, and financial and time toxicities shape shared decision-making in frontline EGFR-mutated non-small cell lung cancer (NSCLC), and whether subcutaneous amivantamab has changed his colleague’s risk-benefit assessment. Dr. Doroshow argues quality of life, time, and financial toxicity cannot be separated from efficacy, because efficacy is determined in a trial vacuum while effectiveness depends on whether patients can actually receive and tolerate the medicine.
On subcutaneous amivantamab, Dr. Doroshow notes it reduces infusion-related reactions, but FDA-recommended monitoring times remain substantial. She references data from World Lung 2024 (Florez et al.) suggesting time toxicity may not be significantly reduced when those recommendations are followed, though she expects observation periods to shorten with experience. At her institution, patients receiving the first IV amivantamab dose are essentially there all day. Dr. Patel agrees subcutaneous amivantamab is the standard at UC San Diego and is, in his view, a different drug from the patient-experience standpoint.
On the COCOON regimen for cutaneous toxicity prophylaxis, Dr. Doroshow flags that asking patients to layer multiple topicals plus an oral antibiotic is itself time-toxic, and that adherence can be challenging for patients who do not speak English. She emphasizes nurse-reinforced education and refers severe rashes to her oncodermatologist. Dr. Patel agrees prevention is the best treatment, sees patients weekly during the first month for early intervention, and notes dose reduction and brief treatment holds maintain quality of life over a long treatment course.
Related Posts
Sequencing Strategy in EGFR-Mutant NSCLC: How Frontline Choices Shape Later Options
Managing Progression in EGFR-Mutant NSCLC: Re-Biopsy, Small Cell Transformation, and CNS Surveillance
Datopotamab Druxtecan and ADC Toxicity Management in EGFR-Mutant NSCLC
Second-Line Regimen Choice and Re-Biopsy Realities in EGFR-Mutant NSCLC After Osimertinib
MET-Directed Resistance in EGFR-Mutant NSCLC: Testing, Treatment Matching, and Toxicity Management
Closing Reflections and Key Takeaways of Optimizing Treatment Selection and Sequencing in Advanced EGFR-Mutated NSCLC: Balancing Efficacy, Toxicity, and Emerging Evidence
